TrialBMJ open2020

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.

Huijuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.